Arrowhead Pharmaceuticals Soars 10.88% on Q2 Earnings Surprise

On May 13, 2025, Arrowhead Pharmaceuticals surged 10.88% in pre-market trading, marking a significant rise in its stock price.

Arrowhead Pharmaceuticals reported fiscal Q2 earnings late Monday, showing a profit of $2.75 per diluted share, a stark contrast to the loss of $1.02 reported in the same period last year. This positive earnings report is likely a key driver behind the stock's pre-market surge.

Arrowhead Research Corp. announced fiscal second-quarter net income of $370.4 million, reversing a loss from the same period a year earlier. This financial turnaround indicates strong operational performance and strategic successes, contributing to investor confidence and the stock's upward momentum.

The company's earnings release on Monday has been well-received by the market, with the stock price advancing significantly. This positive market reaction underscores the importance of strong financial performance in driving stock value and investor sentiment.